Pr Yohann Loriot
- Specialty
- Oncologist, urology expert
- Title
- Deputy Head of Early Trials department
- Hospital
- Gustave Roussy (Villejuif)
- Latest articles
-
- Plain language summary of the THOR Cohort 1 study comparing treatment with erdafitinib or chemotherapy in advanced or metastatic urothelial cancer. (Jul 1, 2025)
- Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer. (Jun 7, 2025)
- Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease. (Jun 3, 2025)
- Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study. (Jun 1, 2025)
- Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study. (May 14, 2025)